Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance

R. Salani, R. J. Kurman, R. Giuntoli, G. Gardner, R. Bristow, T. L. Wang, I. M. Shih

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance'. Together they form a unique fingerprint.

Medicine & Life Sciences